Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$95.45M

FY 2025 · Annual

Investing Cash Flow

$100.42M

FY 2025 · Annual

Financing Cash Flow

$1.10M

FY 2025 · Annual

-99.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Depreciation & Amortization829K2.64M3.73M3.81M3.11M
Deferred Income Tax(1.51M)0000
Stock-Based Compensation8.33M20.11M26.23M26.97M24.9M
Change in Working Capital7.71M15.79M813K1.74M(3.33M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.34M676K(886K)(1.53M)513K
Other Working Capital6.36M15.11M1.7M3.27M(3.84M)
Other Non-Cash Items27.81M101.01M(6.95M)19.72M4.41M
Operating Cash Flow(79.6M)(103.26M)(101.22M)(109.42M)(95.46M)
Capital Expenditures(18.89M)(16.55M)(1.78M)(22.56M)(128K)
Acquisitions (Net)7.68M4M000
Purchases of Investments(105.82M)(134.33M)(314.39M)(403.38M)(150.97M)
Sales of Investments60.11M79.8M244.95M269.33M261.03M
Other Investing Activities(7.68M)(4M)(20M)(22.5M)(9.5M)
Investing Cash Flow(64.59M)(71.08M)(91.22M)(156.62M)100.43M
Debt Repayment00000
Common Stock Issued317M95.25M1.3M239.06M1.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.01M2.82M01.64M0
Financing Cash Flow439.4M98.08M1.3M240.7M1.1M
Effect of Forex Changes00000
Net Change in Cash295.21M(76.27M)(191.14M)(25.34M)6.07M
Free Cash Flow(98.49M)(119.82M)(102.99M)(131.98M)(95.58M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$124.5M
+ D&A$3.1M
+ Stock-Based Comp$24.9M
+ Deferred Tax$0
- Working Capital-$3.3M
+ Other Non-Cash$4.4M
= Operating Cash Flow-$95.5M
- Capex-$128.0K
= Free Cash Flow-$95.6M

Analysis

FY2025 free cash flow is -$95.6M. FCF conversion is 76.7% of net income. Operating cash flow was -$95.5M, with capex of -$128.0K. The largest bridge item is Stock-Based Comp at $24.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
8-KCurrent reportOct 16, 2026
8-KCurrent reportAug 24, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

Does ERAS generate free cash flow?

Erasca, Inc. (ERAS) generated -$95.58M of free cash flow in fiscal 2025.

How much operating cash flow does ERAS produce?

Operating cash flow was -$95.45M, before capital expenditures of $128,000.00.